Impact of HER2 Overexpression and Coexpression of Hormonal Receptors on Pathological Response after Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

被引：0
|
作者：
Moscoso, Louis [1 ]
Ruiz-Merino, Guadalupe
Huayna, Lourdes Salazar [1 ]
Iborra-Lacal, Emma
de Romani, Santiago Escriva [2 ]
Jimenez-Lucas, Maria
Raber, Christian Siso [1 ]
Cabezas-Herrera, Juan
Peg, Vicente [1 ]
Ramon Y Cajal, Santiago [3 ]
Pinero-Madrona, Antonio
机构：
[1] Hosp Univ Vall dHebron, Barcelona, Spain
[2] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[3] Vall dHebron Univ Hosp, Barcelona, Spain
来源：
LABORATORY INVESTIGATION | 2022年 / 102卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
152
引用
收藏
页码：168 / 169
页数：2
相关论文
共 50 条
  • [21] Impact of anthracyclines use on pathological complete response to neoadjuvant treatment in HER2-positive breast cancer
    Teixeira, C.
    Goncalves, M.
    Valente, A. C.
    Reis, J.
    Tavares, N.
    Augusto, I.
    Sousa, I.
    Almeida, D.
    Ribeiro, M. J.
    Barbosa, M.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 32 - 32
  • [22] Methodology Used to Determine HER2 Status Correlates with Response to Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer
    Cheng, Esther
    McIntire, Patrick
    D'Alfonso, Timothy
    Ginter, Paula
    MODERN PATHOLOGY, 2018, 31 : 54 - 54
  • [23] Methodology Used to Determine HER2 Status Correlates with Response to Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer
    Cheng, Esther
    McIntire, Patrick
    D'Alfonso, Timothy
    Ginter, Paula
    LABORATORY INVESTIGATION, 2018, 98 : 54 - 54
  • [24] Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer
    Domergue, Camille
    Martin, Elodie
    Lemarie, Camille
    Jezequel, Pascal
    Frenel, Jean-Sebastien
    Augereau, Paule
    Campone, Mario
    Patsouris, Anne
    CANCERS, 2022, 14 (10)
  • [25] Impacts of HER2 immunohistochemical scores on response and outcomes of HER2-positive breast cancers after neoadjuvant therapy
    Chiu, Yun-Ning
    Hsu, Chih-Yi
    Lien, Pei-Ju
    Chao, Ta-Chung
    Liu, Chun-Yu
    Lin, Yen-Shu
    Wang, Yu-Ling
    Tsai, Yi-Fang
    Tseng, Ling-Ming
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2023, 86 (04) : 409 - 417
  • [26] HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma
    Hou, Yanjun
    Nitta, Hiroaki
    Wei, Lai
    Banks, Peter M.
    Portier, Bryce
    Parwani, Anil V.
    Li, Zaibo
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 166 (02) : 447 - 457
  • [27] HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma
    Yanjun Hou
    Hiroaki Nitta
    Lai Wei
    Peter M. Banks
    Bryce Portier
    Anil V. Parwani
    Zaibo Li
    Breast Cancer Research and Treatment, 2017, 166 : 447 - 457
  • [28] HER2Δ16 expression in HER2-positive breast cancer
    De Yao, Jocelyn Torres
    Sun, Danyu
    Galehouse, Donna
    Shorten, Scott
    Haller, Nairmeen
    Rehmus, Esther Hoogland
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] Multimodality Imaging Review of HER2-positive Breast Cancer and Response to Neoadjuvant Chemotherapy
    Portnow, Leah H.
    Kochkodan-Self, Jeanne M.
    Maduram, Amy
    Barrios, Mirelys
    Onken, Allison M.
    Hong, Xuefei
    Mittendorf, Elizabeth A.
    Giess, Catherine S.
    Chikarmane, Sona A.
    RADIOGRAPHICS, 2023, 43 (02)
  • [30] HER2Δ16 expression in HER2-positive breast cancer
    De Yao, Jocelyn Torres
    Sun, Danyu
    Galehouse, Donna
    Shorten, Scott
    Haller, Nairmeen Awad
    Rehmus, Esther Hoogland
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (26)
12345